nach oben

Erschienen in:

14.01.2021 | Original Article

Evaluation of clinical findings and neurofibromatosis type 1 bright objects on brain magnetic resonance images of 60 Turkish patients with NF1 gene variants

verfasst von: Filiz Hazan, Semra Gürsoy, Aycan Unalp, Unsal Yılmaz, Bengü Demirağ, Sultan Aydin Köker, Berk Ozyılmaz, Kadri Murat Erdogan, Önder Kalenderer, Serkan Erkuş, Müge Gürçınar, Ajlan Tükün

Erschienen in: Neurological Sciences | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Neurofibromatosis type 1 (NF1) is caused by mutations in the NF1 gene. This retrospective study aims to evaluate the clinical manifestations and brain magnetic resonance images (MRI) analysis in 60 genetically confirmed NF1 patients. The results of next-generation sequencing (NGS), Sanger sequencing, and MLPA of NF1 gene were evaluated. A total of 54 different variants were identified. Fourteen out of them were novel variants (25.9%). Patients who complied with NIH criteria had most frequently frameshift variants (11/32 patients), and those with only CALMs had missense variants (9/28 patients). Neurofibromatosis type 1 bright objects (NBOs) on T2-weighted MRI were detected in 42 patients (42/56; 75%). These brain lesions were detected mostly in basal ganglia and in cerebellar vermis. NBOs were detected more in the patients who complied with NIH criteria (80.6%) compared to those who were only CALMs (68%). While frameshift variants (33.3%) were the most common type variants in the patients who had NBOs, the most common variants were splicing (35.7%) and missense (35.7%) variants in the patients whose MRIs were normal. Frameshift variants (11/28 patients; 39.3%) were the most common in the patients with more than one brain locus involvement. Therefore, we consider that frameshift variants may be associated with increased incidence of NBOs and involvement of more than one brain locus. In addition, NBOs may occur less frequently in the patients with splicing variants. To our knowledge, this is the first study evaluated the relationship between NF1 gene variants and NBOs. Future studies may help us understand the etiology of NBOs.

Hirbe AC, Gutmann DH (2014) Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 13:834–843PubMed

National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma (1991) The consensus development panel (1994). Arch Neurol 51:201–207

Ferrari F, Masurel A, Olivier-Faivre L, Vabres P (2014) Juvenile xanthogranuloma and nevus anemicus in the diagnosis of neurofibromatosis type 1. JAMA Dermatol 150:42–46PubMed

Tekin M, Bodurtha JN, Riccardi VM (2001) Cafe au lait spots: the pediatrician’s perspective. Pediatr Rev 22:82–90PubMed

Nunley KS, Gao F, Albers AC et al (2009) Predictive value of café au lait macules at initial consultation in the diagnosis of neurofibromatosis type 1. Arch Dermatol 145:883–887PubMed

Bayat M, Bayat A (2020) Neurological manifestations of neurofibromatosis: a review. Neurol Sci 41:2685–2690PubMed

Baudou E, Nemmi F, Biotteau M, Maziero S, Peran P, Chaix Y (2020) Can the cognitive phenotype in neurofibromatosis type 1 (NF1) be explained by neuroimaging? A review. Front Neurol 10:1373PubMedPubMedCentral

Lopes Ferraz Filho JR, Munis MP, Soares Souza A et al (2008) Unidentified bright objects on brain MRI in children as a diagnostic criterion for neurofibromatosis type 1. Pediatr Radiol 38:305–310PubMed

Wallace MR, Marchuk DA, Andersen LB et al (1990) Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249:181–186PubMed

10.

Cawthon RM, Weiss R, Xu GF et al (1990) A majör segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 62:193–201PubMed

11.

Martin GA, Viskochil D, Bollag G et al (1990) The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63:843–849PubMed

12.

Xu GF, O'Connell P, Viskochil D et al (1990) The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 62:599–608PubMed

13.

Bollag G, McCormick F (1991) Differential regulation of ras GAP and neurofibromatosis gene product activities. Nature 351:576–579PubMed

14.

Marchuk DA, Saulino AM, Tavakkol R et al (1991) cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics 11:931–940PubMed

15.

Yu H, Zhao X, Su B, Li D, Xu Y, Luo S, Xiao C, Wang W (2005) Expression of NF1 pseudogenes. Hum Mutat 26:487–488PubMed

16.

Castle B, Baser ME, Huson SM, Cooper DN, Upadhyaya M (2003) Evaluation of genotype-phenotype correlations in neurofibromatosis type 1. J Med Genet 40:e109PubMedPubMedCentral

17.

Ulusal SD, Gürkan H, Atlı E et al (2017) Genetic analyses of the NF1 gene in Turkish neurofibromatosis type I patients and definition of three novel variants. Balkan J Med Genet 20:13–20PubMedPubMedCentral

18.

Pasmant E, de Saint-Trivier A, Laurendeau I, Dieux-Coeslier A, Parfait B, Vidaud M, Vidaud D, Bièche I (2008) Characterization of a 7.6-Mb germline deletion encompassing the NF1 locus and about a hundred genes in an NF1 contiguous gene syndrome patient. Eur J Hum Genet 16:1459–1466PubMed

19.

Zhu L, Zhang Y, Tong H, Shao M, Gu Y, du X, Wang P, Shi L, Zhang L, Bi M, Wang X, Zhang G (2016) Clinical and molecular characterization of NF1 patients: single-center experience of 32 patients from China. Medicine (Baltimore) 95:e3043

20.

Richards S, Aziz N, Bale S, ACMG Laboratory Quality Assurance Committee et al (2015) ACMG laboratory quality assurance committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405–424CrossRefPubMedPubMedCentral

21.

Adzhubei I, Jordan DM, Sunyaev SR (2013) Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet 76(Chapter 7):Unit7.20

22.

Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4:1073–1081PubMed

23.

Schwarz JM, Cooper DN, Schuelke M et al (2014) MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods 11:361–362PubMed

24.

Upadhyaya M (2010) Neurofibromatosis type 1: diagnosis and recent advances. Expert Opin Med Diagn 4:307–322PubMed

25.

Jett K, Friedman JM (2010) Clinical and genetic aspects of neurofibromatosis 1. Genet Med 12:1–11PubMed

26.

Bianchessi D, Morosini S, Saletti V, Ibba MC, Natacci F, Esposito S, Cesaretti C, Riva D, Finocchiaro G, Eoli M (2015) 126 novel mutations in Italian patients with neurofibromatosis type 1. Mol Genet Genomic Med 3:513–525PubMedPubMedCentral

27.

Palma Milla C, Lezana Rosales JM, López Montiel J et al (2018) Neurofibromatosis type I: mutation spectrum of NF1 in spanish patients. Ann Hum Genet 82:425–436PubMed

28.

Barrea C, Vaessen S, Bulk S et al (2018) Phenotype-genotype correlation in children with neurofibromatosis type 1. Neuropediatrics 49:180–184PubMed

29.

Alwan S, Tredwell SJ, Friedman JM (2005) Is osseous dysplasia a primary feature of neurofibromatosis 1 (NF1)? Clin Genet 67:378–390PubMed

30.

Van Minkelen R, van Bever Y, Kromosoeto JN et al (2014) A clinical and genetic overview of 18 years neurofibromatosis type 1 molecular diagnostics in the Netherlands. Clin Genet 85:318–327PubMed

31.

Tsipi M, Poulou M, Fylaktou I, Kosma K, Tsoutsou E, Pons MR, Kokkinou E, Kitsiou-Tzeli S, Fryssira H, Tzetis M (2018) Phenotypic expression of a spectrum of neurofibromatosis type 1 (NF1) mutations identified through NGS and MLPA. J Neurol Sci 395:95–105PubMed

32.

Giugliano T, Santoro C, Torella A et al (2019) Clinical and genetic findings in children with neurofibromatosis type 1, Legius syndrome, and other related neurocutaneous disorders. Genes (Basel) 10:580

33.

Messiaen LM, Callens T, Mortier G et al (2000) Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 15:541–555PubMed

34.

Zatkova A, Messiaen L, Vandenbroucke I, Wieser R, Fonatsch C, Krainer AR, Wimmer K (2004) Disruption of exonic splicing enhancer elements is the principal cause of exon skipping associated with seven nonsense or missense alleles of NF1. Hum.Mutat 24:491–501PubMed

35.

Mattocks C, Baralle D, Tarpey P, ffrench-Constant C, Bobrow M, Whittaker J (2004) Automated comparative sequence analysis identifies mutations in 89% of NF1 patients and confirms a mutation cluster in exons 11–17 distinct from the GAP related domain. J Med Genet 41:e48PubMedPubMedCentral

36.

Zhang J, Tong H, Fu X et al (2015) Molecular characterization of NF1 and neurofibromatosis type 1 genotype-phenotype correlations in a Chinese population. Sci Rep 5:11291PubMedPubMedCentral

37.

Ars E, Kruyer H, Morell M, Pros E, Serra E, Ravella A, Estivill X, Lázaro C (2003) Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients. J Med Genet 40:e82PubMedPubMedCentral

38.

Pasmant E, Vidaud M, Vidaud D, Wolkenstein P (2012) Neurofibromatosis type 1: from genotype to phenotype. J Med Genet 49:483–489PubMed

39.

De Raedt T, Brems H, Wolkenstein P et al (2003) Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet 72:288–1292

40.

Kluwe L, Siebert R, Gesk S, Friedrich RE, Tinschert S, Kehrer-Sawatzki H, Mautner VF (2004) Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene. Hum Mutat 23:111–116PubMed

41.

Pasmant E, Sabbagh A, Spurlock G, Laurendeau I, Grillo E, Hamel MJ, Martin L, Barbarot S, Leheup B, Rodriguez D, Lacombe D, Dollfus H, Pasquier L, Isidor B, Ferkal S, Soulier J, Sanson M, Dieux-Coeslier A, Bièche I, Parfait B, Vidaud M, Wolkenstein P, Upadhyaya M, Vidaud D, members of the NF France Network (2010) NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat 31:E1506–E1518PubMed

42.

Ning X, Farschtschi S, Jones A, Kehrer-Sawatzki H, Mautner VF, Friedman JM (2016) Growth in neurofibromatosis 1 microdeletion patients. Clin Genet 89:351–354PubMed

43.

Kehrer-Sawatzki H, Mautner VF, Cooper DN (2017) Emerging genotype-phenotype relationships in patients with large NF1 deletions. Hum Genet 136:349–376PubMedPubMedCentral

44.

Friedman JM. Neurofibromatosis 1. In: Adam MP, Ardinger HH, Pagon RA et al (eds) GeneReviews. University of Washington, pp 1993–2020

45.

Prada CE, Hufnagel RB, Hummel TR et al (2015) The use of magnetic resonance imaging screening for optic pathway gliomas in children with neurofibromatosis type 1. J Pediatr 167:851–856PubMedPubMedCentral

46.

Sellmer L, Farschtschi S, Marangoni M, Heran MKS, Birch P, Wenzel R, Mautner VF, Friedman JM (2018) Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1. Orphanet J Rare Dis 13:62PubMedPubMedCentral

47.

Blanchard G, Lafforgue MP, Lion-François L et al (2016) Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort. Eur J Paediatr Neurol 20:275–281PubMed

48.

DeBella K, Poskitt K, Szudek J, Friedman JM (2000) Use of “unidentified bright objects” on MRI for diagnosis of neurofibromatosis 1 in children. Neurology 54:1646–1650PubMed

49.

Mentzel HJ, Seidel J, Fitzek C et al (2005) Pediatric brain MRI in neurofibromatosis type I. Eur Radiol 15:814–822PubMed

Titel: Evaluation of clinical findings and neurofibromatosis type 1 bright objects on brain magnetic resonance images of 60 Turkish patients with NF1 gene variants
verfasst von: Filiz Hazan
Semra Gürsoy
Aycan Unalp
Unsal Yılmaz
Bengü Demirağ
Sultan Aydin Köker
Berk Ozyılmaz
Kadri Murat Erdogan
Önder Kalenderer
Serkan Erkuş
Müge Gürçınar
Ajlan Tükün
Publikationsdatum: 14.01.2021
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 5/2021
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04988-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2021

Ischemic stroke/transient ischemic attack in adults with primary immune thrombocytopenia: a meta-analysis

Economic burden of medication-overuse headache in Iran: direct and indirect costs

Risk factors predicting recurrence of transient global amnesia

Factors affecting the behavior of children with ASD during the first outbreak of the COVID-19 pandemic

Discovery of specific mutations in spinal muscular atrophy patients by next-generation sequencing